In 2019, 54gene launched with a bold mission: to fix one of medicine’s biggest global blind spots, the lack of African representation in genetic research.

African populations are the most genetically diverse in the world, yet most global drug development is built on European genetic data. That imbalance affects diagnostics, treatment accuracy, and drug discovery.

54gene set out to change that by building one of the largest genomic databases of African populations and partnering with pharmaceutical companies to advance precision medicine.

The mission was clear and solid. So what changed?

The Issue: Biotech Is Slow And Expensive.

In 2 years, 54gene expanded rapidly, with significant international funding. 

However, this rapid progress came to a stop in 2023. The company had to downsize and shut part of its operations. 

and entered a period of financial distress.

So what exactly changed? Note that the issue wasn’t the mission. The challenge came from the structure.  

Biotech is fundamentally different from software. It is capital-intensive, infrastructure-heavy and slow to monetise. From day one, 54gene needed laboratory facilities, specialised scientists, regulatory compliance systems, secure genomic data architecture and clinical partnerships. These are not optional costs; they are foundational.

Revenue in biotech doesn’t come quickly, unlike fintech or e-commerce. Drug discovery cycles are long. That means costs start immediately, but returns take time.

54gene scaled during the global venture capital boom of 2020-2021. A time when investors were comfortable with the long-term game of biotech’s ROI.

The Pressure of a Capital-Heavy Model

By 2022, things changed. Global tech markets cooled, venture funding tightened, and investors prioritised faster paths to profitability and lower burn rates.

For a company dependent on continued funding for research and infrastructure, that shift was critical. When funding becomes cautious, capital-heavy startups feel it first.

During its growth phase, 54gene expanded operations, increased headcount and broadened its activities to include diagnostics. Expansion increased fixed costs across salaries, facilities, equipment and operational overhead. When funding slowed, those costs remained.

The company eventually had to lay off employees, shut down parts of its diagnostics operations and restructure leadership in an effort to manage funds.

Another structural challenge was commercialisation. 54gene’s revenue model relied heavily on pharmaceutical research partnerships, data licensing and collaborative drug discovery projects. These deals are complex and slow-moving. Negotiation, compliance and validation take time. Revenue did not scale at the pace required to support recurring operating expenses, and in a tighter funding environment, that mismatch became unsustainable.

So was it a failure?

Not in the actual sense. The problem 54gene set out to solve still exists. African genomic data remains underrepresented in global research. The scientific need has not disappeared.

But biotech requires patient capital, long investment horizons and disciplined cost management. When a long-term scientific mission meets a short-term venture funding cycle, tension builds. 54gene’s crisis reflects that structural mismatch.

In many African startup ecosystems, the dominant playbook is built around software businesses that scale quickly and generate early revenue. Biotech operates differently. It moves more slowly. It costs more. It requires sustained investor conviction.

54gene’s story is less about a flawed idea and more about structural pressure, heavy operating costs, slower-than-expected commercialisation and a global funding slowdown. In emerging markets, those factors compound quickly.

The mission was ambitious. The environment changed. And in biotech, timing and capital structure matter as much as vision.